Evidence map›Paper›PMID 31676590›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

BRAF

Terence M Williams

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Terence M WilliamsThe Ohio State University Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, Ohio. terence.williams@osumc.edu.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPOREP50CA168505 · NCI · OHIO STATE UNIVERSITY · PI DE LA CHAPELLE, ALBERT · 2013 to 2017
$10.9M
The Ohio State University Center for Clinical and Translational ScienceKL2TR001068 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$2.7M
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic CancerR01CA198128 · NCI · OHIO STATE UNIVERSITY · PI WILLIAMS, TERENCE MARQUES · 2016 to 2021
$2.4M
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid CancerR01CA246553 · NCI · OHIO STATE UNIVERSITY · PI WILLIAMS, TERENCE MARQUES · 2020 to 2025
$2.0M
NCATS NIH HHS KL2 TR001068NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA168505NCI NIH HHS R01 CA198128NCI NIH HHS R01 CA246553
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNAHumansOncogenesProto-Oncogene Proteins B-rafThyroid NeoplasmsBRAF protein, humanDNAProto-Oncogene Proteins B-raf

Identifiers

PMID31676590
PMCPMC6903400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.